Laser Capture Microdissection

LCM Process Image

Theranostics Health utilizes Laser Capture Microdissection (LCM) to isolate purified or enriched populations of cells from heterogeneous tissue samples. When LCM and RPPA technologies are employed in an integrated manner, one can approach the specificity of conventional immunochemistry analysis (via LCM) while capitalizing on the high throughput proteomic pathway analysis capabilities that the RPPA platform offers for analyzing preclinical and clinical tissue samples.

Typically, only a few tissue sections from a core needle biopsy are required to analyze up to fifty RPPA assays which can allow for a thorough measurement of a drug target’s activation, its downstream signaling pathway, as well as potential compensatory or survival pathways that are activated in response to a drug treatment.

Proteomic analysis services that utilize our LCM capabilities can be performed on either frozen or formalin-fixed, paraffin-embedded (FFPE) tissue samples, and are performed under the supervision of Theranostics Health’s in-house, board-certified pathologist.